NAMS MENOPAUSE CERTIFICATION EXAM
CERTIFICATION GUIDE QUESTIONS AND
100% VERIFIED ANSWERS WITH RATIONALES
GRADED A+
GUARANTEED PASS ON THE FIRST ATTEMPT
1.
A 49-year-old woman reports irregular menses over the past year and new-onset
hot flashes. Which hormonal change most strongly supports early menopausal
transition?
A. Decreased FSH
B. Increased estradiol
C. Elevated FSH
D. Decreased LH
Answer: C
Rationale: Early menopausal transition is marked by fluctuating estrogen levels
and rising FSH due to decreased ovarian reserve.
2.
A 55-year-old woman with a history of hysterectomy seeks hormone therapy for
vasomotor symptoms. What is the most appropriate regimen?
A. Combined estrogen-progestin
B. Estrogen alone
C. Progesterone alone
D. Testosterone therapy
,Answer: B
Rationale: Women without a uterus do not require progestin; estrogen alone is
appropriate and avoids unnecessary progestin exposure.
3.
Which route of estrogen administration is associated with a lower risk of venous
thromboembolism?
A. Oral estrogen
B. Transdermal estrogen
C. Intramuscular estrogen
D. Vaginal ring estrogen (systemic dose)
Answer: B
Rationale: Transdermal estrogen bypasses hepatic first-pass metabolism, reducing
clotting factor activation and VTE risk.
4.
A 52-year-old woman reports painful intercourse due to vaginal dryness. First-line
therapy includes:
A. Systemic estrogen therapy
B. Vaginal moisturizers and lubricants
C. Oral progesterone
D. Testosterone injections
Answer: B
Rationale: Nonhormonal vaginal moisturizers and lubricants are first-line for mild
dyspareunia.
,5.
Which statement about oral estrogen is correct?
A. It lowers triglycerides
B. It increases triglycerides
C. It has no hepatic effect
D. It reduces clotting factors
Answer: B
Rationale: Oral estrogen increases triglycerides due to hepatic first-pass
metabolism.
6.
A 60-year-old woman, 10 years postmenopause, asks about starting hormone
therapy. What is the primary concern?
A. Increased fertility
B. Increased cardiovascular risk
C. Increased bone density
D. Reduced breast cancer risk
Answer: B
Rationale: Initiating hormone therapy >10 years after menopause is associated
with increased cardiovascular risk.
7.
Which symptom is most strongly associated with vasomotor instability?
A. Dyspareunia
B. Night sweats
C. Osteoporosis
D. Urinary incontinence
Answer: B
, Rationale: Night sweats and hot flashes are hallmark vasomotor symptoms.
8.
A patient prefers nonhormonal treatment for hot flashes. Which is an evidence-
based option?
A. SSRIs
B. Calcium supplements
C. Antibiotics
D. Insulin
Answer: A
Rationale: SSRIs/SNRIs are effective nonhormonal treatments for vasomotor
symptoms.
9.
Which study significantly influenced hormone therapy recommendations?
A. Framingham Study
B. Women's Health Initiative
C. Nurses’ Health Study
D. DASH Trial
Answer: B
Rationale: The WHI demonstrated risks associated with combined hormone
therapy, influencing guidelines.
10.
A 51-year-old woman with intact uterus is prescribed estrogen therapy. What must
be added?
A. Testosterone
B. Progestin
CERTIFICATION GUIDE QUESTIONS AND
100% VERIFIED ANSWERS WITH RATIONALES
GRADED A+
GUARANTEED PASS ON THE FIRST ATTEMPT
1.
A 49-year-old woman reports irregular menses over the past year and new-onset
hot flashes. Which hormonal change most strongly supports early menopausal
transition?
A. Decreased FSH
B. Increased estradiol
C. Elevated FSH
D. Decreased LH
Answer: C
Rationale: Early menopausal transition is marked by fluctuating estrogen levels
and rising FSH due to decreased ovarian reserve.
2.
A 55-year-old woman with a history of hysterectomy seeks hormone therapy for
vasomotor symptoms. What is the most appropriate regimen?
A. Combined estrogen-progestin
B. Estrogen alone
C. Progesterone alone
D. Testosterone therapy
,Answer: B
Rationale: Women without a uterus do not require progestin; estrogen alone is
appropriate and avoids unnecessary progestin exposure.
3.
Which route of estrogen administration is associated with a lower risk of venous
thromboembolism?
A. Oral estrogen
B. Transdermal estrogen
C. Intramuscular estrogen
D. Vaginal ring estrogen (systemic dose)
Answer: B
Rationale: Transdermal estrogen bypasses hepatic first-pass metabolism, reducing
clotting factor activation and VTE risk.
4.
A 52-year-old woman reports painful intercourse due to vaginal dryness. First-line
therapy includes:
A. Systemic estrogen therapy
B. Vaginal moisturizers and lubricants
C. Oral progesterone
D. Testosterone injections
Answer: B
Rationale: Nonhormonal vaginal moisturizers and lubricants are first-line for mild
dyspareunia.
,5.
Which statement about oral estrogen is correct?
A. It lowers triglycerides
B. It increases triglycerides
C. It has no hepatic effect
D. It reduces clotting factors
Answer: B
Rationale: Oral estrogen increases triglycerides due to hepatic first-pass
metabolism.
6.
A 60-year-old woman, 10 years postmenopause, asks about starting hormone
therapy. What is the primary concern?
A. Increased fertility
B. Increased cardiovascular risk
C. Increased bone density
D. Reduced breast cancer risk
Answer: B
Rationale: Initiating hormone therapy >10 years after menopause is associated
with increased cardiovascular risk.
7.
Which symptom is most strongly associated with vasomotor instability?
A. Dyspareunia
B. Night sweats
C. Osteoporosis
D. Urinary incontinence
Answer: B
, Rationale: Night sweats and hot flashes are hallmark vasomotor symptoms.
8.
A patient prefers nonhormonal treatment for hot flashes. Which is an evidence-
based option?
A. SSRIs
B. Calcium supplements
C. Antibiotics
D. Insulin
Answer: A
Rationale: SSRIs/SNRIs are effective nonhormonal treatments for vasomotor
symptoms.
9.
Which study significantly influenced hormone therapy recommendations?
A. Framingham Study
B. Women's Health Initiative
C. Nurses’ Health Study
D. DASH Trial
Answer: B
Rationale: The WHI demonstrated risks associated with combined hormone
therapy, influencing guidelines.
10.
A 51-year-old woman with intact uterus is prescribed estrogen therapy. What must
be added?
A. Testosterone
B. Progestin
